최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기생명과학회지 = Journal of life science, v.26 no.7 = no.195, 2016년, pp.826 - 834
문현정 (부산대학교 의학전문대학원 생화학교실) , 이수훈 (부산대학교 의학전문대학원 생화학교실) , 김학봉 (부산대학교 의학전문대학원 생화학교실) , 이경아 (부산대학교 의학전문대학원 생화학교실) , 강치덕 (부산대학교 의학전문대학원 생화학교실) , 김선희 (부산대학교 의학전문대학원 생화학교실)
The present investigation was undertaken to examine the effectiveness of the combination treatment of an Hsp90 inhibitor and a SIRT1 inhibitor on suppressing the growth of chemo-resistant human cancer cells. We showed that inhibition of SIRT1 effectively potentiated the cytotoxicity of 17-allylamino...
* AI 자동 식별 결과로 적합하지 않은 문장이 있을 수 있으니, 이용에 유의하시기 바랍니다.
Anckar, J. and Sistonen, L. 2011. Regulation of HSF1 function in the heat stress response: implications in aging and disease. Annu. Rev. Biochem. 80, 1089-1115.
Bagatell, R., Paine-Murrieta, G. D., Taylor, C. W., Pulcini, E. J., Akinaga, S., Benjamin, I. J. and Whitesell, L. 2000. Induction of a heat shock factor 1-dependent stress response alters the cytotoxic activity of hsp90-binding agents. Clin. Cancer Res. 6, 3312-3318.
Bahr, O., Wick, W. and Weller, M. 2001. Modulation of MDR/MRP by wild-type and mutant p53. J. Clin. Invest. 107, 643-646.
Banerji, U. 2009. Heat shock protein 90 as a drug target:some like it hot. Clin. Cancer Res. 15, 9-14.
Brooks, C. L. and Gu, W. 2009. How does SIRT1 affect metabolism, senescence and cancer? Nat. Rev. Cancer 9, 123-128.
Chin, K. V., Ueda, K., Pastan, I. and Gottesman, M. M. 1992. Modulation of activity of the promoter of the human MDR1 gene by Ras and p53. Science 255, 459-462.
Davenport, E. L., Zeisig, A., Aronson, L. I., Moore, H. E., Hockley, S., Gonzalez, D., Smith, E. M., Powers, M. V., Sharp, S. Y., Workman, P., Morgan, G. J. and Davies, F. E. 2010. Targeting heat shock protein 72 enhances Hsp90 inhibitor-induced apoptosis in myeloma. Leukemia 24, 1804-1807.
El-Deiry, W. S. 2003. The role of p53 in chemosensitivity and radiosensitivity. Oncogene 22, 7486-7495.
Esser, C., Scheffner, M. and Hohfeld, J. 2005. The chaperone-associated ubiquitin ligase CHIP is able to target p53 for proteasomal degradation. J. Biol. Chem. 280, 27443-27448.
Evans, C. G., Chang, L. and Gestwicki, J. E. 2010. Heat shock protein 70 (hsp70) as an emerging drug target. J. Med. Chem. 53, 4585-4602.
Fan, M., Park, A. and Nephew, K. P. 2005. CHIP (carboxyl terminus of Hsc70-interacting protein) promotes basal and geldanamycin-induced degradation of estrogen receptoralpha. Mol. Endocrinol. 19, 2901-2914.
Freed-Pastor, W. A. and Prives, C. 2012. Mutant p53: one name, many proteins. Genes Dev. 26, 1268-1286.
Gan, L. and Mucke, L. 2008. Paths of convergence: sirtuins in aging and neurodegeneration. Neuron 58, 10-14.
Guo, F., Rocha, K., Bali, P., Pranpat, M., Fiskus, W., Boyapalle, S., Kumaraswamy, S., Balasis, M., Greedy, B., Armitage, E. S., Lawrence, N. and Bhalla, K. 2005. Abrogation of heat shock protein 70 induction as a strategy to increase antileukemia activity of heat shock protein 90 inhibitor 17-allylamino-demethoxy geldanamycin. Cancer Res. 65, 10536-10544.
Hong, D. S., Banerji, U., Tavana, B., George, G. C., Aaron, J. and Kurzrock, R. 2013. Targeting the molecular chaperone heat shock protein 90 (HSP90): lessons learned and future directions. Cancer Treat. Rev. 39, 375-387.
Jhaveri, K., Taldone, T., Modi, S. and Chiosis, G. 2012. Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers. Biochim. Biophys. Acta 1823, 742-755.
Kamal, A., Thao, L., Sensintaffar, J., Zhang, L., Boehm, M. F., Fritz, L. C. and Burrows, F. J. 2003. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 425, 407-410.
Keshelava, N., Zuo, J. J., Chen, P., Waidyaratne, S. N., Luna, M. C., Gomer, C. J., Triche, T. J. and Reynolds, C. P. 2001. Loss of p53 function confers high-level multidrug resistance in neuroblastoma cell lines. Cancer Res. 61, 6185-6193.
Kim, D. Y., Kim, M. J., Kim, H. B., Lee, J. W., Bae, J. H., Kim, D. W., Kang, C. D. and Kim, S. H. 2011. Suppression of multidrug resistance by treatment with TRAIL in human ovarian and breast cancer cells with high level of c-Myc. Biochim. Biophys. Acta 1812, 796-805.
Kim, H. B., Lee, S. H., Um, J. H., Kim, M. J., Hyun, S. K., Gong, E. J., Oh, W. K., Kang, C. D. and Kim, S. H. 2015. Sensitization of chemo-resistant human chronic myeloid leukemia stem-like cells to Hsp90 inhibitor by SIRT1 inhibition. Int. J. Biol. Sci. 11, 923-934.
Li, D., Marchenko, N. D. and Moll, U. M. 2011. SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis. Cell Death Differ. 18, 1904-1913.
Li, D., Marchenko,N. D., Schulz,R., Fischer,V., Velasco-Hernandez, T., Talos, F. and Moll, U. M. 2011. Functional inactivation of endogenous MDM2 and CHIP by HSP90 causes aberrant stabilization of mutant p53 in human cancer cells. Mol. Cancer Res. 9, 577-588.
Li, D., Yallowitz, A., Ozog, L. and Marchenko, N. 2014. A gain-of-function mutant p53-HSF1 feed forward circuit governs adaptation of cancer cells to proteotoxic stress. Cell Death Dis. 5, e1194.
McCollum, A. K., Teneyck, C. J., Sauer, B. M., Toft, D. O. and Erlichman, C. 2006. Up-regulation of heat shock protein 27 induces resistance to 17-allylamino-demethoxygeldanamycin through a glutathione-mediated mechanism. Cancer Res. 66, 10967-10975.
McCollum, A. K., TenEyck, C. J., Stensgard, B., Morlan, B. W., Ballman, K. V., Jenkins, R. B., Toft, D. O. and Erlichman, C. 2008. P-Glycoprotein-mediated resistance to Hsp90-directed therapy is eclipsed by the heat shock response. Cancer Res. 68, 7419-7427.
Modi, S., Stopeck, A., Linden, H., Solit, D., Chandarlapaty, S., Rosen, N., D′Andrea, G., Dickler, M., Moynahan, M. E., Sugarman, S., Ma, W., Patil, S., Norton, L., Hannah, A. L. and Hudis, C. 2011. HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab. Clin. Cancer Res. 17, 5132-5139.
Moulick, K., Ahn, J. H., Zong, H., Rodina, A., Cerchietti, L., Gomes DaGama, E. M., Caldas-Lopes, E., Beebe, K., Perna, F., Hatzi, K., Vu, L. P., Zhao, X., Zatorska, D., Taldone, T., Smith-Jones, P., Alpaugh, M., Gross, S. S., Pillarsetty, N., Ku, T., Lewis, J. S., Larson, S. M., Levine, R., Erdjument-Bromage, H., Guzman, M. L., Nimer, S. D., Melnick, A., Neckers, L. and Chiosis, G. 2011. Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90. Nat. Chem. Biol. 7, 818-826.
Muller, P., Hrstka, R., Coomber, D., Lane, D. P. and Vojtesek, B. 2008. Chaperone-dependent stabilization and degradation of p53 mutants. Oncogene 27, 3371-3383.
Oh, W. K., Cho, K. B., Hien, T. T., Kim, T. H., Kim, H. S., Dao, T. T., Han, H. K., Kwon, S. M., Ahn, S. G., Yoon, J. H., Kim, T. H., Kim, Y. G. and Kang, K. W. 2010. Amurensin G, a potent natural SIRT1 inhibitor, rescues doxorubicin responsiveness via down-regulation of multidrug resistance 1. Mol. Pharmacol. 78, 855-864.
Pacey, S., Gore, M., Chao, D., Banerji, U., Larkin, J., Sarker, S., Owen, K., Asad, Y., Raynaud, F., Walton, M., Judson, I., Workman, P. and Eisen, T. 2012. A Phase II trial of 17-allylamino, 17-demethoxygeldanamycin (17-AAG, tanespimycin) in patients with metastatic melanoma. Invest. New Drugs 30, 341-349.
Piper, P. W. and Millson, S. H. 2011. Mechanisms of resistance to Hsp90 inhibitor drugs: a complex mosaic emerges. Pharmaceuticals 4, 1400-1422.
Powers, M. V. and Workman, P. 2007. Inhibitors of the heat shock response: biology and pharmacology. FEBS Lett. 581, 3758-3769.
Richardson, P. G., Chanan-Khan, A. A., Lonial, S., Krishnan, A. Y., Carroll, M. P., Alsina, M., Albitar, M., Berman, D., Messina, M. and Anderson, K. C. 2011. Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 study. Br. J. Haematol. 153, 729-740.
Richardson, P. G., Mitsiades, C. S., Laubach, J. P., Lonial, S., Chanan-Khan, A. A. and Anderson, K. C. 2011. Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers. Br. J. Haematol. 152, 367-379.
Sampath, J., Sun, D., Kidd, V. J., Grenet, J., Gandhi, A., Shapiro, L. H., Wang, Q., Zambetti, G. P. and Schuetz, J. D. 2001. Mutant p53 cooperates with ETS and selectively up-regulates human MDR1 not MRP1. J. Biol. Chem. 276, 39359-39367.
Solit, D. B., Osman, I., Polsky, D., Panageas, K. S., Daud, A., Goydos, J. S., Teitcher, J., Wolchok, J. D., Germino, F. J., Krown, S. E., Coit, D., Rosen, N. and Chapman, P. B. 2008. Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanoma. Clin. Cancer Res. 14, 8302-8307.
Strauss, B. E. and Haas, M. 1995. The region 3′ to the major transcriptional start site of the MDR1 downstream promoter mediates activation by a subset of mutant P53 proteins. Biochem. Biophys. Res. Commun. 217, 333-340.
Takara, K., Sakaeda, T. and Okumura, K. 2006. An update on overcoming MDR1-mediated multidrug resistance in cancer chemotherapy. Curr. Pharm. Des. 12, 273-286.
Taldone, T., Gozman, A., Maharaj, R. and Chiosis, G. 2008. Targeting Hsp90: small-molecule inhibitors and their clinical development. Curr. Opin. Pharmacol. 8, 370-374.
Vilaboa, N. E., Galan, A., Troyano, A., de Blas, E. and Aller, P. 2000. Regulation of multidrug resistance 1 (MDR1)/Pglycoprotein gene expression and activity by heat-shock transcription factor 1 (HSF1). J. Biol. Chem. 275, 24970-24976.
Westerheide, S. D., Anckar, J., Stevens, S. M., Jr., Sistonen, L. and Morimoto, R. I. 2009. Stress-inducible regulation of heat shock factor 1 by the deacetylase SIRT1. Science 323, 1063-1066.
Yamakuchi, M. and Lowenstein, C. J. 2009. MiR-34, SIRT1 and p53: the feedback loop. Cell Cycle 8, 712-715.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.